Open AccessAccrual, Publication Bias, and the Coronavirus in 2020
Author(s) -
Bates Susan E.
Publication year - 2020
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2020-0455
Subject(s) - medicine , transparency (behavior) , accrual , covid-19 , clinical trial , publication bias , medline , coronavirus , alternative medicine , clinical practice , family medicine , pathology , meta analysis , infectious disease (medical specialty) , law , accounting , disease , earnings , outbreak , political science , business
The era of COVID19 reflects the importance, perhaps now more than ever, of transparency in the outcomes of trials small and large. The Oncologist Clinical Trial Results (CTR) section has endeavored to provide a remedy for the persistent problem of underreporting in clinical trials in oncology and the subsequent publication bias that this practice necessarily creates. As The Oncologist celebrates its 25th Anniversary, we focus not only on the ethical and moral imperatives behind CTR, but also on the practical goal of informing the practice of treating physicians.